Citigroup restated a buy rating on shares of Intensity Therapeutics.
1 report, 1 independent
Updated Oct 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup restated a buy rating on shares of Intensity Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup restated a buy rating on shares while Societe Generale Group was noted as a France-based group.
- Citigroup reaffirmed a buy rating on BTI shares, and Capital Research Global Investors acquired shares of BTI.
- Citigroup reaffirmed a market outperform rating for HealthEquity.
- Citigroup and Royal Bank of Canada issued rating and price objective updates on shares of Brunello Cucinelli.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.